University at Buffalo - The State University of New York
Skip to Content
UBMD Physicians' Group

Clinical Trials

Warfarin vs. Aspirin in Reduced Cardiac Ejection Fraction

Warfarin vs. Aspirin in Reduced Cardiac Ejection Fraction

The purpose of this study is to determine whether warfarin (INR) or aspirin (325 mg/day) is superior for preventing all cause mortality and stroke combined in patients with ejection fraction (EF) < 30% when balanced against any risk of intra-cerebral hemorrhage.

Eligibility

PATIENTS WITH A LOW EJECTION FRACTION WITH HEART FAILURE

Reimbursement

YES

Investigator

DR. SUSAN GRAHAM Sub Investigator: Virginia Hart, RN

Contact Information

Name: MARY BONORA
Phone: 716.859.4641
Email: MBONORA@KALEIDAHEALTH.ORG